# Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain

> **NCT06077422** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 150 (estimated)

## Conditions studied

- Pain, Postoperative
- Opioid Use
- Perioperative Complication
- Heart Diseases

## Interventions

- **DRUG:** bupivacaine liposome injectable suspension
- **DRUG:** Bupivacaine Hydrochloride

## Key facts

- **NCT ID:** NCT06077422
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-01-11
- **Primary completion:** 2027-01-11
- **Final completion:** 2027-04-05
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06077422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06077422, "Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06077422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*